soul trial oral semaglutide cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes | Cardiovascular Diabetology SOUL (Semaglutide cardiOvascular oUtcomes triaL)

The maintenance phase demonstrates whether achieved benefits persist with reduced intensity protocols or whether more aggressive approaches are necessary to sustain improvements

Leave the patch in place for up to 12 hours

mBio 2023, 14, mbio03404

Bedford, MA, USA)

In addition, dichloroacetic acid (DCA), a pyruvate dehydrogenase activator, enhanced cardiac efficiency during IRI of isolated rat hearts by increasing glucose oxidation (59)

As such, it is not surprising that providers still incorrectly document or screen for obesity, and that recognition of obesity as a disease remains low, including in patients with T2D